Answers are grounded in this paper and cite their sources.
Background Traumatic brain injury (TBI) increases long-term risk for cognitive decline and neurodegeneration, motivating objective blood biomarkers that can be measured repeatedly over time. However, reliance on venipuncture limits longitudinal monitoring, particularly outside clinic settings. Objective We conducted a pilot feasibility study comparing fingerstick capillary blood collected as dried plasma spots (DPS) with matched venous EDTA plasma for quantification of glial fibrillary acidic protein (GFAP) and neurofilament light (NfL). Methods Paired samples were collected prospectively across matched time points spanning hours to decades post-injury and assayed using high-sensitivity immunoassays. Results Absolute protein recovery from DPS was lower and more variable than venous plasma, but paired GFAP and NfL measurements remained well-correlated. We further evaluated the GFAP/NfL ratio as an internal, sample-based normalization strategy and observed improved concordance between capillary DPS and venous plasma compared with either analyte alone. Conclusions These pilot findings support the analytical feasibility of capillary DPS sampling for GFAP and NfL measurement in TBI and identify the GFAP/NfL ratio as an exploratory internal-normalization approach. Formal analytical and clinical validation — including outcome linkage and prospective evaluation — will be required before capillary DPS can be considered for clinical monitoring applications. Highlights First high-frequency (twice-daily for 14 days) paired capillary-DPS / venous-plasma GFAP and NfL trajectories in acute TBI (Cohort #1, n = 4). Strong within-subject capillary-venous correlations for GFAP (ρ up to 0.647) and NfL (ρ up to 0.902); the GFAP / NfL ratio reaches ρ = 0.797–0.977. Cross-sectional capillary-DPS biomarkers separate acute, subacute, and chronic TBI populations across a multi-site cohort (Cohort #2). Concurrent work by Bouthors et al. (CCLM 2026) supports prioritizing GFAP and NfL over UCH-L1 for capillary panels because UCH-L1 is intra-erythrocytic and hemolysis-sensitive. Capillary DPS sampling establishes analytical feasibility for paired capillary–venous GFAP and NfL measurement; formal validation of context-of-use, unsupervised collection, and outcome linkage is required before clinical deployment.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: